Home > Neurology > Combination treatment fails to improve survival in recurrent glioma

Combination treatment fails to improve survival in recurrent glioma

Journal
JAMA Oncology
Reuters Health - 04/11/2020 - Following tumor resection in patients with recurrent glioblastoma and anaplastic astrocytoma, treatment with vocimagene amiretrorepvec (Toca 511) and with flucytosine (Toca FC) provides no improvement in overall survival, according to an open-label phase 2/3 trial. "Unfortunately," Dr. Michael A. Vogelbaum told Reuters Health by email, "glioblastoma remains a highly aggressive form of cancer with few effective therapies. The same was the case for decades for multiple other forms of cancers that we now consider to be routinely treatable, and we will continue to pursue new strategies." The standard of care for these aggressive brain tumors involves maximal safe resection plus radiotherapy and concurrent chemotherapy with temozolomide followed by temozolomide maintenance therapy, Dr. Vogelbaum of the H. Lee Moffitt Center, in Tampa, Florida, and colleagues note in JAMA Oncology. But nearly all high-grade gliomas eventually recur, wi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on